These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. An unusual reoccurrence of Waldenstrom's macroglobulinemia as pleural effusions that had a discordant response with treatment. Amin CJ; Rabinowitz I Clin Lab Haematol; 2005 Jun; 27(3):200-2. PubMed ID: 15938727 [TBL] [Abstract][Full Text] [Related]
29. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. Byrd JC; White CA; Link B; Lucas MS; Velasquez WS; Rosenberg J; Grillo-López AJ Ann Oncol; 1999 Dec; 10(12):1525-7. PubMed ID: 10643548 [TBL] [Abstract][Full Text] [Related]
30. Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia. Hellmann A; Lewandowski K; Zaucha JM; Bieniaszewska M; Hałaburda K; Robak T Eur J Haematol; 1999 Jul; 63(1):35-41. PubMed ID: 10414453 [TBL] [Abstract][Full Text] [Related]
31. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. Dimopoulos MA; Kantarjian H; Weber D; O'Brien S; Estey E; Delasalle K; Rose E; Cabanillas F; Keating M; Alexanian R J Clin Oncol; 1994 Dec; 12(12):2694-8. PubMed ID: 7989946 [TBL] [Abstract][Full Text] [Related]
32. Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia. Gavriatopoulou M; Kastritis E; Kyrtsonis MC; Vassilakopoulos TP; Roussou M; Fotiou D; Migkou M; Mpakiri M; Tasidou A; Terpos E; Dimopoulos MA Leuk Lymphoma; 2017 Jun; 58(6):1506-1508. PubMed ID: 27724158 [No Abstract] [Full Text] [Related]
34. Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies. Johnson SA Hematol J; 2004; 5 Suppl 1():S50-61. PubMed ID: 15079153 [TBL] [Abstract][Full Text] [Related]
38. Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients. Tamburini J; Lévy V; Chaleteix C; Fermand JP; Delmer A; Stalniewicz L; Morel P; Dreyfus F; Grange MJ; Christian B; Choquet S; Leblond V Leukemia; 2005 Oct; 19(10):1831-4. PubMed ID: 16121217 [TBL] [Abstract][Full Text] [Related]
39. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E; J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550 [TBL] [Abstract][Full Text] [Related]
40. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease. Leblond V; Lévy V; Maloisel F; Cazin B; Fermand JP; Harousseau JL; Remenieras L; Porcher R; Gardembas M; Marit G; Deconinck E; Desablens B; Guilhot F; Philippe G; Stamatoullas A; Guibon O; Blood; 2001 Nov; 98(9):2640-4. PubMed ID: 11675332 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]